NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO
The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today,
For further information on the Rights Issue, please see the published Prospectus.
Summary of the terms
- Rights issue of a maximum of 15,052,083 units (15,052,083 B shares and 15,052,083 warrants of series TO1) corresponding to, upon full subscription, total proceeds of approximately
SEK 30.1 million before issue costs. -
Subscription commitments of approximately
SEK 2.1 million in total have been received from the Company's largest shareholderSivlerSkog Group AB , which is owned by the founders Petter Sivlér andMårten Skog , as well as the Company's chairman of the boardFredrik Skog and several other existing shareholders. Guarantee undertakings of approximatelySEK 19.0 million , up to a total of approximatelySEK 21.1 million in the Rights Issue, have been received from a number of external investors. The rights issue is thus guaranteed up to 70 percent through subscription commitments and guarantee undertakings. - For each existing share held on the record date, one (1) unit right is received in the Rights Issue. Holding of one (1) unit right entitles to subscribe for one (1) new unit. One unit (1) consists of one (1) B-share and one (1) warrant of series TO1.
-
Subscription price of
SEK 2.00 per unit (SEK 2.00 per share). The warrants are issued free of charge. -
The subscription price for subscription of Class B shares by exercising warrants of series TO1 shall correspond to 70 percent of the volume-weighted average price paid for the Company's shares on the Nasdaq First North Growth Market during the period from and including
22 August 2022 up to and including30 September 2022 , however not lower than the quota value of the share. -
The exercise period for warrants of series TO1 runs from and including
6 October 2022 up to and including20 October 2022 .
Preliminary timetable regarding the Rights Issue
Last day of trading in shares of the company including the right to receive unit rights | |
First trading day in the share excluding the right to receive unit rights | |
Record date regarding the Rights Issue | |
22 April - | Trading in unit rights |
22 April - | Subscription period for the Rights Issue |
Estimated date for publication of the Rights Issue results |
Advisors
Contact information
Petter Sivlér - CEO,
Phone: +46 (0)8-70 000 50
E-Mail: petter.sivler@s2m.se
Certified Adviser
Phone +46 (0)8-580 065 99
Website: www.vatorsec.se
E-mail: ca@vatorsec.se
About
The ticker of the share: S2M
The ISIN-code of the share: SE0011725084
IMPORTANT INFORMATION
In certain jurisdictions, the publication, announcement or distribution of this press release may be subject to restrictions according to law. Persons in such jurisdictions where this press release has been published or distributed should inform themselves, observe and abide by such restrictions. The recipient of this press release is responsible for using this press release, and the information herein, in accordance with applicable rules in the respective jurisdiction. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO, OR AN INVITATION TO, ACQUIRE OR SUBSCRIBE ANY SECURITIES IN THE COMPANY IN ANY JURISDICTION, NOT FROM THE COMPANY OR ANY OTHER PERSON.
This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. A PROSPECTUS, CORRESPONDING TO AN EU GROWTH PROSPECTUS, WILL BE PREPARED BY THE COMPANY AND PUBLISHED ON THE COMPANY'S WEBSITE AFTER THE PROSPECTUS HAS BEEN REVIEWED AND APPROVED BY THE SWEDISH FINANCIAL SUPERVISORY AUTHORITY.
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OR INVITATION CONCERNING THE ACQUISITION OR SUBSCRIPTION OF SECURITIES IN
In the
FORWARD-LOOKING STATEMENTS
TO THE EXTENT THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, SUCH STATEMENTS DO NOT REPRESENT FACTS AND ARE CHARACTERIZED BY WORDS THAT "WILL", "ARE EXPECTED", "BELIEVES", "ESTIMATES", "INTENDS", "ASSUMES" AND SIMILAIR EXPRESSIONS. SUCH STATEMENTS EXPRESS S2MEDICAL'S INTENTIONS, OPINIONS OR CURRENT EXPECTATIONS OR ASSUMPTIONS. SUCH FUTURE STATEMENTS ARE BASED ON CURRENT PLANS, ESTIMATES AND FORECASTS WHICH S2MEDCIAL HAS MADE TO THE BEST PERFORMANCE BUT WHICH S2MEDICAL DOES NOT SAY IN THE COMING TOMORROW. FUTURE STATEMENTS ARE COMBINED WITH RISKS AND UNCERTAINTIES THAT ARE DIFFICULT TO PREDICT AND IN GENERAL CANNOT BE AFFECTED BY S2MEDICAL. IT SHOULD BE KEEPED IN MIND THAT ACTUAL EVENTS OR OUTCOMES MAY DIFFER SIGNIFICANTLY FROM WHAT IS COVERED BY, OR EXPRESSED FOR, IN SUCH FORWARD-LOOKING STATEMENTS.
INFORMATION TO DISTRIBUTORS
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in s2medical have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in s2medical may decline and investors could lose all or part of their investment; the shares in s2medical offer no guaranteed income and no capital protection; and an investment in the shares in s2medical is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Share Issue. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.
For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in s2medical.
Each distributor is responsible for undertaking its own target market assessment in respect of the shares in s2medical and determining appropriate distribution channels.
The information was submitted for publication, through the agency of the contact person, on
Contact Details
Petter Sivlér - CEO,
Telephone: +46 (0)8-70 000 50
E-mail: petter.sivler@s2m.se
Certified Adviser
Telephone +46 (0)8-580 065 99
Website: www.vatorsec.se
E-mail: ca@vatorsec.se
About
Share's ticker: S2M
Share's ISIN-code: SE0011725084
https://news.cision.com/s2medical-ab/r/s2medical-ab--publ--publishes-eu-growth-prospectus-in-connection-with-the-forthcoming-rights-issue-o,c3546756
https://mb.cision.com/Main/17719/3546756/1564617.pdf
(c) 2022 Cision. All rights reserved., source